

June 19, 2025

BrightPath Presented Data on Bispecific Antibody BP1212 for Cancer Therapy at IRCI 2025

Tokyo, Japan – June 19, 2025/ -- BrightPath Biotherapeutics (“BrightPath”, TSE Growth 4954), a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics, announced that it has presented the new data on its bispecific antibody BP1212 for the treatment of cancer at the Immune Response in Cancer and Infection (IRCI) 2025 held in Lyon, France on June 18-20, 2025.

The abstract and poster have been made available on the website of [BrightPath](https://www.brightpathbio.com).

BP1212 is a humanized bispecific antibody that targets TIM-3 and CD39, which are co-expressed on tumor-infiltrating dendritic cells and exhausted cytotoxic T lymphocytes (CTLs). These molecules are known to be key negative regulators of inflammasome signaling, a critical component of innate immunity. By blocking both targets, BP1212 promotes inflammasomes in dendritic cells and triggers anti-tumor immune responses.

Key findings presented at IRCI 2025 include:

- Potent tumor regression by promoting inflammasome signaling
- Functional enhancement of dendritic cells in the tumor
- Enhanced cytotoxicity and tumor infiltration of CTLs
- Favorable safety and pharmacokinetic profiles in NHP models
- A formulation profile and stable manufacturing for clinical development

BP1212 is currently under development as a novel immunotherapy approach for treatment-resistant cancers.

Presentation Title:

“Cancer immunotherapy by promoting inflammasomes in dendritic cells”
(Abstract No. 10)

Presentation Time:

12:45 p.m. CEST / 7:45 p.m. JST, Thursday, June 19, 2025

About BrightPath Biotherapeutics

BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies, currently in clinical trials, and immunomodulatory antibodies.

For more information, visit www.brightpathbio.com/English

Investor and Media Contact:

irpr@brightpathbio.com

www.brightpathbio.com/English/